DR. RAMI OWERA

WOODLANDS MEDICAL SPECIALISTS
Department of Hematology-Oncology

FELLOWSHIP
Fellowship of Hematology Oncology,
University of Missouri
Ellis Fischel Cancer Center
Columbia, Missouri

RESIDENCY
Residency of Internal Medicine
University of Missouri
Columbia, Missouri

INTERNSHIP
Internship of Internal Medicine
University of Missouri
Columbia, Missouri

MEDICAL SCHOOL
Doctorate of Medicine
Aleppo University, School of Medicine

AFFILIATIONS/ACHIEVEMENTS

  • Diplomate of the American Board of Medical Oncology
  • Diplomate of the American Board of Hematology
  • State Licensed in Florida and Alabama
  • Principal Investigator for Woodlands’ Clinical Research

  • Member of the American Society of Clinical Oncology
  • Member of the American Society of Hematology
  • Clerkship Faculty, College of Medicine – Florida State University

CLINICAL RESEARCH & PUBLICATIONS

  • USOR 20137: go41854: A phase iii, open-label, randomized study of Atezolizumab and Tiragolumab compared with Durvalumab in patients with locally advanced, unresectable stage iii non-small cell lung cancer who have not progressed after concurrent platinum-based chemoradiation (skyscraper-03)
  • USOR 19236: A phase iii, multicenter, randomized, open-label study to evaluate the efficacy and safety of Atezolizumab given in combination with Cabozantinib versus Cabozantinib alone in patients with inoperable, locally advanced, or metastatic renal cell carcinoma who experienced radiographic tumor progression during or after immune checkpoint inhibitor treatment (wo41994)
  • USOR 19191: A Phase III, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer (CheckMate 7DX: CHECKpoint pathway and nivoluMAB clinical Trial Evaluation 7DX) (CA209-7DX)
  • USOR 17213: A Phase III, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette- Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)
  • USOR 18095: A Phase III, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer (CA017078)
  • USOR 19094: QBGJ398-302: Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)
  • USOR 17101: A Phase III,  Randomized, Double-Blind Trial of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB024360) or Placebo in Participants with Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307) (3475-672)
  • USOR 17081: C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen (Phase IV)
  • USOR 17103: A Randomized, Open-Label, Phase III,  Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) plus Epacadostat vs Standard of Care (Sunitinib or Pazopanib) as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-679/ECHO-302)
  • USOR 18283: A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy (IMMU-132-06)
  • (PIVOT 10) NKTR 18-214-10: A Phase II,  randomized non-comparative open-label study of NKTR-214 in combination with nivolumab and of chemotherapy in cisplatin ineligible, locally advanced or metastatic urothelial cancer patients with PD-L1-negative disease.
  • USOR 16251: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)
  • USOR 17027: SYD985.002: A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician’s choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer
  • USOR 17040: A Phase I/II Study of HDAC Inhibitor, Mocetinostat, in Combination With PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (0103-020)
  • USOR 17132: A Phase III, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) as adjuvant Therapy after Definitive Local Therapy in Patients with High Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck (WO40242)
  • USOR 18031: A Phase I/II study of pegzilarginase (AEB1102, Co-ArgI-PEG) in combination with pembrolizumab in the treatment of patients with extensive disease (ED) small cell lung cancer (SCLC) (CAEB1102-101B)
  • USOR 18065: A Phase II, Multicenter, Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer(MS200647-0037)
  • USOR 18109: A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects With Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta® (pegfilgrastim) Onpro® kit or Other Physician Choice Options for Prophylaxis of FN (20170758)
  • USOR 18150: Treatment Resistance Following Anti-Cancer Therapies (TRANSLATE) (A9001502)
  • USOR 16140: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)
  • USOR 18127: Treatment Patterns, Outcomes, and Patient-Reported Health-Related Quality of Life: A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents (D8220R00004)
  • USOR 19151: A Phase I/II Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
  • USOR 19084: A Single-Arm, Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies (BGB-3111-216)
  • USOR 19144: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)
  • USOR 20206: The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice (007)
  • BRE 161: Phase III Trial of Amrubicin as Second-or Third-Line Treatment for Patients with HER2-Negative Metastatic Breast Cancer
  • CLL 11: Phase II Trial of Ofatumumab for Older Patients and Patients who Refuse Fludarabine-8ased Regimens with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
  • MDS 04-21: A Phase III, Multi-Center, Randomized, Controlled Study to Assess the Efficacy and Safety of ON 01910.Na Administered as a 72-Hour Continuous Intravenous Infusion Every Other Week in Myelodysplastic Syndrome Patients with Excess Blasts Relapsing After, or Refractory to, or Intolerant to Azacitidine or Decitabine
  • GU75: Randomized, Multicenter, Open-Label, Active-Controlled, Phase 2 Study of LY2510924 and Sunitinib verses Sunitinib in Patients with Metastatic Renal Cell Carcinoma (RCC)
  • GI 148: A Phase II Study of the Hsp90 Inhibitor AUY922 for the Treatment of Patients with Refractory Gastrointestinal Stromal Tumor (GIST)
  • LUN 218: A Randomized Phase 2 Study of LY2510924 and Carboplatin/Etoposide verses Carboplatin/Etoposide in Extensive Stage Small Cell Lung Carcinoma (12v-MC-CXAC)
  • BRE-185: A Randomized Phase 2 Study of LY2523355 versus Ixabepilone in Patients with Metastatic or Locally Recurrent Breast Cancer Who Have Received Prior Taxane Therapy
  • GI 154: A Phase II Trial of Single Agent Axitinib as Maintenance Therapy for Patients with First Line Metastatic Colorectal Cancer (mCRC)
  • BRE-197: A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer
  • LYM: 75: Phase II Study of Bendamustine and Ofatumumab in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Who are Poor Candidates for R-CHOP Chemotherapy
  • MM27: Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma
  • LYM 87: A Phase II Study of IPI-145 in Subjects with Refractory Indolent Non-Hodgkin Lymphoma
  • GI 168: A Phase II Study of 5-Fluorouracil (5-FU), Aflibercept, and Radiation for the Preoperative and Adjuvant Treatment of Patients with Stage II/III Rectal Cancer
  • GI 166: A Phase II Study with Lead-in Safety Cohort of 5-Fluorouracil, Oxaliplatin and Lapatinib in Combination with Radiation Therapy as Neoadjuvant Treatment for Patients with Localized HER2 Positive Esophagogastric Adenocarcinomas
  • REVEAL: Prospective Observational Study of Patients with Polycythemia Vera in US Clinical Practices
  • ASCO Abstract: High incidence of hypersensitivity reactions to Cetuximab infusions in mid-Missouri: Association with prior history of atopy. ID: 20747
  • Hodgkin’s lymphoma-Internal Medicine Just the facts-chapter 68-p 414-416.
  • Esophageal carcinoma- Internal Medicine Just the facts- p 471-472.
  • Gastric carcinoma- Internal Medicine Just the facts- p 472-473.
  • Colorectal cancer – Internal Medicine Just the facts- p 469-471.
  • Pancreatic carcinoma- Internal Medicine Just the facts- p 473-474.
  • The use of R-CVP in refractory acquired hemophilia A-Case report.
  • Hepatocellular carcinoma -Internal Medicine Just the facts- p 474-475.

CONTACT INFORMATION

  • (850) 696 4000

  • 4724 North Davis Highway
    Pensacola, FL 32503

  • 1301 Belleville Avenue,
    Brewton, Alabama 36426

HOURS

Monday – Friday 8:00 – 5:00

LOCATIONS

NORTH DAVIS

BREWTON, ALABAMA